Prosecution Insights
Last updated: April 19, 2026

Gi Innovation Inc.

4 pending office actions

Portfolio Summary

4
Total Pending OAs
1
Final Rejections
3
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18549558 FORMULATION OF FUSION PROTEIN INCLUDING EXTRACELLULAR DOMAIN OF ALPHA SUBUNIT OF IGE FC RECEPTOR REGLAS, GEORGIANA C 1651 Final Rejection Sep 07, 2023
18005752 FUSION PROTEIN COMPRISING IGE FC RECEPTOR ALPHA SUBUNIT EXTRACELLULAR DOMAIN AND ANTI-IL-4R ANTIBODY, AND USE THEREOF LANDSMAN, ROBERT S 1647 Non-Final OA Jan 17, 2023
18004872 FUSION PROTEIN INCLUDING GLUCAGON-LIKE PEPTIDE-1 AND INTERLEUKIN-1 RECEPTOR ANTAGONIST AND USE THEREOF CHANDRA, GYAN 1674 Non-Final OA Jan 09, 2023
18003123 FUSION PROTEIN COMPRISING ANTI-LAG-3 ANTIBODY AND IL-2, AND USE THEREOF D' AMBROSIO, THEA 1654 Non-Final OA Dec 22, 2022

Managing Gi Innovation Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month